newsfilter
← Latest News
Business Wire·

AVT02, Alvotech's Biosimilar to High Concentration Formulation of Adalimumab (Humira®) Approved for Use in European Union

Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, received approval for AVT02 (100 mg/mL), the company's high concentration biosimila